Telmisartan Tablets

Telmisartan is a specific angiotensin II receptor (ATⅠ type) antagonist. Telmisartan replaces angiotensin II receptors and binds to ATⅠ receptor subtypes (known angiotensin II action sites) with high affinity. Telmisartan has no agonist effect at any site on the ATⅠ receptor site. Telmisartan selectively binds to ATⅠ receptors and the binding effect is long-lasting. Telmisartan has no affinity for other receptors (including AT2 and other AT receptors with fewer characteristics). The functions of the above other receptors are not yet known, and the excessive receptor stimulation effect that may be caused by the increase in angiotensin II levels caused by telmisartan is also unknown. Telmisartan does not inhibit human plasma renin or block ion channels. Telmisartan does not inhibit angiotensin converting enzyme II, which can also degrade bradykinin and cause adverse reactions. In humans, administration of 80 mg of telmisartan can almost completely inhibit the increase in blood pressure caused by angiotensin II. The inhibitory effect lasts for 24 hours and can still be measured after 48 hours. The antihypertensive effect gradually becomes apparent within 3 hours after the first dose of telmisartan. The maximum antihypertensive effect can be achieved 4 weeks after the start of treatment and can be maintained in long-term treatment. If telmisartan treatment is suddenly interrupted, blood pressure gradually returns to pre-treatment levels after a few days without rebound hypertension. In a clinical trial directly comparing two antihypertensive drugs, the incidence of dry cough in the telmisartan treatment group was significantly lower than that in the angiotensin-converting enzyme inhibitor treatment group.

The main ingredient of this product is telmisartan.

This product is white tablets.

Used for the treatment of essential hypertension.

1. Adults: Individualized dosing is recommended. The usual initial dose is 1 tablet. This product can be used in combination with thiazide diuretics such as hydrochlorothiazide. This type of diuretic has a synergistic antihypertensive effect with this product. Because telmisartan can only exert its maximum efficacy after 4 to 8 weeks of medication, this should be considered if you want to increase the drug dose. 2. Patients with renal insufficiency: Patients with mild or moderate renal impairment do not need to adjust the dose of this product. Telmisartan cannot be eliminated by hemodialysis. 3. Patients with hepatic insufficiency: Patients with mild or moderate hepatic insufficiency should not take more than 1 tablet per day. 4. Elderly: No dose adjustment is required for this product. 5. Children and adolescents: For children and adolescents under 18 years old, the safety and efficacy data of this product have not yet been established.

Adverse reactions are classified by frequency as follows: very common (1/10); common (1/100, 1/10); uncommon (1/1000, 1/100); rare (1/10000, 1/100); very rare (1/10000). 1. Systemic reactions. Common: back pain (such as sciatica), chest pain, flu-like symptoms, symptoms of infection (such as urinary tract infection including cystitis). Rare: abnormal vision, excessive sweating. 2. Central and peripheral nervous system: Common: dizziness. 3. Gastrointestinal system: Common: abdominal pain, diarrhea, indigestion, gastrointestinal dysfunction. Rare: abnormal vision, excessive sweating. 4. Musculoskeletal system: Common: joint pain, leg cramps or leg pain, myalgia. 5. Nervous system: Rare: anxiety. 6. Respiratory system: Common: upper respiratory tract infections including pharyngitis and rhinitis. 7. Skin and accessory system: Common: skin abnormalities such as eczema. 8. In addition, since telmisartan was launched, individual cases have reported erythema, itching, syncope, insomnia, depression, stomach discomfort, vomiting, hypotension, bradycardia, tachycardia, dyspnea, eosinophilia, thrombocytopenia, weakness, and decreased work efficiency. Similar to other angiotensin II antagonists, very few cases have reported angioedema, urticaria, and other related adverse reactions.

1. Those who are allergic to the active ingredients and any of the excipients of this product. 2. Those in the second or third trimester of pregnancy and breastfeeding. 3. Patients with biliary obstructive diseases. 4. Patients with severe liver dysfunction. 5. Patients with severe renal dysfunction (creatinine clearance 30ml/min).

Precautions for children: For children and adolescents under 18 years old, the safety and efficacy data of this product have not been established. Precautions for pregnancy and lactation: 1. Use during pregnancy: There is not enough data to show whether this product can be used in pregnant women. Animal experiments did not show teratogenicity, but showed embryotoxicity. Therefore, for the sake of caution, do not use telmisartan in the first three months of pregnancy. Before planning pregnancy, appropriate alternative therapies should be taken. In the middle and late stages of pregnancy (during the second and third months), drugs that directly act on the renin-angiotensin system can cause damage to the fetus or even death, so telmisartan is contraindicated in the middle and late stages of pregnancy. Once pregnancy is confirmed, this product should be discontinued as soon as possible. 2. Use during lactation: Since it is not known whether this product is excreted through breast milk, this product is contraindicated during lactation. Precautions for the elderly: No dosage adjustment is required when taking this product.

1. Lithium. The combination of lithium and angiotensin converting enzyme inhibitors can cause reversible increases in blood lithium levels and toxic reactions. There are also individual cases caused by the combination of lithium and angiotensin II receptor antagonists. Therefore, lithium and this product should be used with caution. If combined use is necessary, the blood potassium level should be monitored during the combined use. 2. Some drugs can affect blood potassium levels or cause hyperkalemia (such as ACE inhibitors, potassium-sparing diuretics, potassium ion diuretics, potassium ion supplements, potassium-containing salt substitutes, cyclosporine A or other drugs such as heparin sodium); if this product needs to be used in combination with these drugs, it is recommended to monitor blood potassium levels. Based on the experience of using other drugs that affect the renin-angiotensin system, the combination of this product with the above drugs can cause an increase in blood potassium levels (see Precautions). 3. Pharmacokinetic studies have studied the interaction between this product and digoxin, warfarin, hydrochlorothiazide, glibenclamide, ibuprofen, acetaminophen, amlodipine and other drugs. It can increase the average trough blood concentration of digoxin by 20% (in some cases by 39%), so the peak plasma concentration of digoxin must be monitored. 4. This product can enhance the antihypertensive effect of other antihypertensive drugs. Other clinical interactions have not yet been confirmed. 5. Based on their pharmacological properties, the following drugs can enhance the antihypertensive effect of antihypertensive drugs including telmisartan: baclofen, amifostine. In addition, alcohol, barbiturates, sedatives, hypnotics or antidepressants can enhance the effect of postural hypotension.

Keep in a light-proof and airtight container.

40mg

48 months.

Hainan Selection Pharmaceutical Co., Ltd.

• Founded in:

  2001-03-12

• Address:

  No. 6 Shunda Road, Meilan District, Haikou City

• Tax NO.:

  91460000721284605J

• Registered Funds:

  30 million yuan

• Email:

  Log in to view